Mahmoud H Mosli1, Brian G Feagan2, Guangyong Zou3, William J Sandborn4, Geert D'Haens5, Reena Khanna6, Cynthia Behling7, Keith Kaplan8, David K Driman9, Lisa M Shackelton10, Kenneth A Baker10, John K MacDonald10, Margaret K Vandervoort10, Mark A Samaan10, Karel Geboes11, Mark A Valasek12, Rish Pai13, Cord Langner14, Robert Riddell15, Noam Harpaz16, Maida Sewitch17, Michael Peterson18, Larry W Stitt19, Barrett G Levesque4. 1. Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada Department of Medicine, Western University, London, Ontario, Canada Department of Medicine, King Abdulaziz University, Jeddah, Saudi Arabia Department of Epidemiology, Biostatistics and Occupational Medicine, McGill University, Montreal, Canada. 2. Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada Department of Medicine, Western University, London, Ontario, Canada Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. 3. Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada. 4. Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada Division of Gastroenterology, University of California San Diego, La Jolla, California, USA. 5. Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada Department of Gastroenterology, Academic Medical Center, Amsterdam, The Netherlands. 6. Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada Department of Medicine, Western University, London, Ontario, Canada. 7. Pacific Rim Pathology Medical Corporation, San Diego, California, USA. 8. Carolinas Medical Center, Charlotte, North Carolina, USA. 9. Department of Pathology, Western University, London, Ontario, Canada. 10. Robarts Clinical Trials, Robarts Research Institute, Western University, London, Ontario, Canada. 11. Department of Pathology, University Hospital of KU Leuven and UZ Gent, Leuven, Belgium. 12. Department of Pathology, University of California, San Diego, California, USA. 13. Department of Anatomic Pathology, Cleveland Clinic, Cleveland, Ohio, USA. 14. Department of Pathology, Medical University of Graz, Graz, Austria. 15. Department of Pathology, Mount Sinai Hospital, University of Toronto, Toronto, Ontario, Canada. 16. Department of Pathology, Mount Sinai Hospital, New York, New York, USA. 17. Department of Medicine, McGill University, Montreal, Quebec, Canada. 18. Department of Pathology, Western Washington Pathology and Multicare Health System, Tacoma, Washington, USA. 19. Department of Epidemiology and Biostatistics, Western University, London, Ontario, Canada.
Abstract
OBJECTIVE: Histopathology is potentially an important outcome measure in UC. Multiple histological disease activity (HA) indices, including the Geboes score (GS) and modified Riley score (MRS), have been developed; however, the operating properties of these instruments are not clearly defined. We assessed the reproducibility of existing measures of HA. DESIGN: Five experienced pathologists with GI pathology fellowship training and expertise in IBD evaluated, on three separate occasions at least two weeks apart, 49 UC colon biopsies and scored the GS, MRS and a global rating of histological severity using a 100 mm visual analogue scale (VAS). The reproducibility of each grading system and for individual instrument items was quantified by estimates of intraclass correlation coefficients (ICCs) based on two-way random effects models. Uncertainty of estimates was quantified by 95% two-sided CIs obtained using the non-parametric cluster bootstrap method. Biopsies responsible for the greatest disagreement based on the ICC estimates were identified. A consensus process was used to determine the most common sources of measurement disagreement. Recommendations for minimising disagreement were subsequently generated. RESULTS: Intrarater ICCs (95% CIs) for the total GS, MRS and VAS scores were 0.82 (0.73 to 0.88), 0.71 (0.63 to 0.80) and 0.79 (0.72 to 0.85), respectively. Corresponding inter-rater ICCs were substantially lower: 0.56 (0.39 to 0.67), 0.48 (0.35 to 0.66) and 0.61 (0.47 to 0.72). Correlation between the GS and VAS was 0.62 and between the MRS and VAS was 0.61. CONCLUSIONS: Although 'substantial' to 'almost perfect' ICCs for intrarater agreement were found in the assessment of HA in UC, ICCs for inter-rater agreement were considerably lower. According to the consensus process results, standardisation of item definitions and modification of the existing indices is required to create an optimal UC histological instrument. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
OBJECTIVE: Histopathology is potentially an important outcome measure in UC. Multiple histological disease activity (HA) indices, including the Geboes score (GS) and modified Riley score (MRS), have been developed; however, the operating properties of these instruments are not clearly defined. We assessed the reproducibility of existing measures of HA. DESIGN: Five experienced pathologists with GI pathology fellowship training and expertise in IBD evaluated, on three separate occasions at least two weeks apart, 49 UC colon biopsies and scored the GS, MRS and a global rating of histological severity using a 100 mm visual analogue scale (VAS). The reproducibility of each grading system and for individual instrument items was quantified by estimates of intraclass correlation coefficients (ICCs) based on two-way random effects models. Uncertainty of estimates was quantified by 95% two-sided CIs obtained using the non-parametric cluster bootstrap method. Biopsies responsible for the greatest disagreement based on the ICC estimates were identified. A consensus process was used to determine the most common sources of measurement disagreement. Recommendations for minimising disagreement were subsequently generated. RESULTS: Intrarater ICCs (95% CIs) for the total GS, MRS and VAS scores were 0.82 (0.73 to 0.88), 0.71 (0.63 to 0.80) and 0.79 (0.72 to 0.85), respectively. Corresponding inter-rater ICCs were substantially lower: 0.56 (0.39 to 0.67), 0.48 (0.35 to 0.66) and 0.61 (0.47 to 0.72). Correlation between the GS and VAS was 0.62 and between the MRS and VAS was 0.61. CONCLUSIONS: Although 'substantial' to 'almost perfect' ICCs for intrarater agreement were found in the assessment of HA in UC, ICCs for inter-rater agreement were considerably lower. According to the consensus process results, standardisation of item definitions and modification of the existing indices is required to create an optimal UC histological instrument. Published by the BMJ Publishing Group Limited. For permission to use (where not already granted under a licence) please go to http://group.bmj.com/group/rights-licensing/permissions.
Authors: Robert Battat; Niels Vande Casteele; Rish K Pai; Zhongya Wang; Guangyong Zou; John W D McDonald; Marjolijn Duijvestein; Jenny Jeyarajah; Claire E Parker; Tanja Van Viegen; Sigrid A Nelson; Brigid S Boland; Siddharth Singh; Parambir S Dulai; Mark A Valasek; Brian G Feagan; Vipul Jairath; William J Sandborn Journal: Aliment Pharmacol Ther Date: 2020-09-27 Impact factor: 8.171
Authors: Robert Battat; Parambir S Dulai; Christopher Ma; Vipul Jairath; Brian G Feagan; William J Sandborn; Reena Khanna Journal: Curr Treat Options Gastroenterol Date: 2020-01-04
Authors: Mahmoud H Mosli; Claire E Parker; Sigrid A Nelson; Kenneth A Baker; John K MacDonald; G Y Zou; Brian G Feagan; Reena Khanna; Barrett G Levesque; Vipul Jairath Journal: Cochrane Database Syst Rev Date: 2017-05-25
Authors: Kevin Randall; Neil Henderson; Jaimini Reens; Sonia Eckersley; Ann-Christin Nyström; Marie C South; Clare A Balendran; Gerhard Böttcher; Glen Hughes; Sally A Price Journal: PLoS One Date: 2016-09-06 Impact factor: 3.240
Authors: W J Sandborn; B R Bhandari; R Fogel; J Onken; E Yen; X Zhao; Z Jiang; D Ge; Y Xin; Z Ye; D French; J A Silverman; B Kanwar; G M Subramanian; J G McHutchison; S D Lee; L M Shackelton; R K Pai; B G Levesque; B G Feagan Journal: Aliment Pharmacol Ther Date: 2016-05-24 Impact factor: 8.171
Authors: Pim J Koelink; Manon E Wildenberg; Larry W Stitt; Brian G Feagan; Martin Koldijk; Angélique B van 't Wout; Raja Atreya; Michael Vieth; Johannan F Brandse; Suzanne Duijst; Anje A Te Velde; Geert R A M D'Haens; Barrett G Levesque; Gijs R van den Brink Journal: J Crohns Colitis Date: 2018-06-28 Impact factor: 9.071